The Middleman No One Invited to Dinner.

Diagnosis was counted. Care was not.

One child. Two clocks.

Counted by NAWI. Not counted.

The table · four views

Who is served. Who keeps waiting.

A private layer now sits between diagnosis and funded care.

The official clock stops while the family remains at the table.

Administration is funded in full while therapy remains capped.

Timely funded support stays out of reach while the system manages the queue.

There is a national effort underway to fix something everyone agrees is broken: the time children wait for autism care. The National Child Autism Waitlist Initiative (NAWI, housed under the Autism Alliance of Canada) is standardizing how that wait gets measured across provinces, so the numbers can finally be compared, benchmarked and reported on a public dashboard.¹ On its own terms it sounds unarguable. You cannot fix what you do not measure.

But read what NAWI has decided to measure. In September 2024 the initiative convened clinical site leaders and a group of parents to define the key milestones (the “Date of Referral,” the “Wait Time”) and reached consensus on those definitions. Every one of them sits inside the diagnostic process: from the moment a child is referred to the moment a clinician confirms or rules out autism.¹

That is one wait. It is real, and for many families it runs from several months to a couple of years. But it is not the wait that has made Ontario notorious.

The first wait is the wait for a diagnosis: referral, to assessment, to verdict. The second begins the day the diagnosis is delivered: the wait for the funded therapy the diagnosis is supposed to bring. In Ontario, that second wait is where children disappear. Of the 91,974 children registered in the Ontario Autism Program as of May 2026, just 20,711 (fewer than one in four) hold a funding agreement for services. The other 71,263 are waiting. The reported wait is 5+ years for families registered in August 2021 (community-reported, Ontario Autism Coalition, July 2026).²

NAWI’s metric captures the first wait. It ends at diagnosis. The second wait, the years a diagnosed child spends with a binder full of paperwork and no therapist, falls entirely outside the number.

The wait a parent actually lives has three legs, not one:

• First concern → referral. The “wait and see,” the rounds of GP visits, the months it takes just to get onto a referral list. Often one to three years.
• Referral → diagnosis. The diagnostic assessment queue itself. Months to roughly two years.
• Diagnosis → funded therapy. In Ontario, the OAP core-funding wait. Reported: 5+ years for families registered in August 2021 (community-reported, Ontario Autism Coalition, July 2026).

NAWI’s clock starts at the second leg (the “Date of Referral”) and stops at the end of it, the day a diagnosis is confirmed. The first leg and the third, the two longest, both fall outside the window. NAWI’s own account concedes that the pre-referral period “is currently not captured,” and the entire metric is scoped to assessment and diagnosis.¹ The third leg, the funding wait, never enters the frame at all, because OAP funding is a post-diagnosis service and the clock has already stopped.

Put real durations on it. The structure below is documented; the specific years are an illustrative example, not NAWI’s own figures:

• Month 0: a parent first raises a concern. The lived wait begins.
• Month ~12: the referral is finally logged. ← the NAWI clock starts
• Month ~24: an autism diagnosis is delivered. ← the NAWI clock stops, reporting a wait of about 12 months
• Month ~84: funded therapy actually begins. The lived wait ends.

Lived wait: about seven years. NAWI-reported wait: about twelve months. Nobody fabricated the twelve months. It is a real interval, just not the wait.

NAWI does not hide that it measures diagnostic wait; it says so plainly. The distortion comes from what happens when that number becomes the national wait-time figure on a public dashboard, with no competing national number standing beside it for the funding wait. “Autism wait time: twelve months” gets read by reporters, the public, and politicians as the wait for autism help rather than the wait for an assessment. A dashboard built on time-to-diagnosis can show steady improvement (more clinics, shorter diagnostic queues) while the number of children waiting for actual therapy stays exactly where it is. And because the multi-year funding leg has no standardized national metric of its own, it produces no benchmark and no figure to quote. The number that would embarrass a government never gets generated, because the system was never asked to generate it.

It matters who set the boundary. NAWI’s wait-time consensus was reached by diagnostic clinicians, the people whose work sits at the diagnostic stage.¹

No accusation is made here. It is a structural fact with a predictable consequence. Ask the people who run the diagnostic bottleneck to define “the wait,” and you will get a definition that centers the diagnostic bottleneck. The metric validates the part of the system they can see and measure, and quietly excludes the part (funded treatment) that lives in a different budget, under a different ministry, with a far longer queue.

The convergence

The party with money on the table.

The market that forms around a line

The connection shown is this article’s interpretation, not proof of a joint plan, contract, or coordination.

To see what the apparatus looks like when it is spending money, look at the Canadian Autism Leadership Summit. It is run by the Autism Alliance of Canada, the same organization that houses NAWI and its diagnostic-wait metric. In April 2026 it held its twelfth annual edition: sold out, three days, at the Fairmont Château Laurier, one of the grandest hotels in Ottawa.⁶

The theme was “Beyond the Now.” The language was “from strategy to action,” “accountability,” “systems change.” The headline event was a full day given over to an AI symposium (“AI and Autism: Innovation for Inclusion”) featuring major technology companies and startups pitching AI platforms to “reduce waitlist burden.”^{6 7} Around it: panels on system navigation, research posters, a leadership award, a federal public-health vice-president, senators, and a concurrent “Autism on the Hill” engagement on Parliament Hill.⁷

The summit also runs on corporate money, and it sells access by tier. The Alliance’s own sponsorship proposal offers “support” levels that have run from $5,000 for an entry “Bronze” session sponsor up to $25,000 and beyond for the lead “Platinum” supporter, the upper tiers buying logo placement across the Summit’s materials and, at the top, the chance to deliver welcoming or closing remarks from the stage.⁸ This is, to be fair, how most non-profit conferences are funded. But it means a company can pay to put its brand on the country’s premier autism-policy gathering, and pay a little more to speak from its podium. That is the same event where the proposed answer to the waitlist is, increasingly, a commercial AI platform.

The list has no therapy money. The entire summit orbits the wait (nearly every session is, in some sense, about the wait), and yet its centre of gravity is conferencing, branding, leadership, and above all technology. The answer offered in the room is an AI platform, a data system, a navigation tool, not a cheque to a provider so that a five-year-old can begin treatment this year instead of at eleven.

This is what managing the smell looks like in practice: a sold-out summit at a grand hotel, themed on accountability, headlined by some of the largest technology companies in the world, convened by the very body that drew the wait-time metric so the funding wait produces no number, while the funding wait itself, the thing the whole gathering is organized around, continues exactly as before.

This does not say that the researchers, self-advocates, and families in the room are acting in bad faith; many are doing serious work, and convening has real value. The point is structural, and it is about proportion. When the most visible, best-funded, most photographed expression of a “waitlist crisis” is a three-day leadership summit with an AI symposium at the Château Laurier, the system has learned to perform concern at a level of polish it has never once brought to actually paying for care.

Strip away the summit and the dashboard and look at the shape of the thing underneath. Between the government that funds autism therapy and the family that needs it, Ontario has inserted a private administrative layer: an intake contractor that registers children, determines their funding, and runs the gate. The question is what that layer is for.

The usual answer deserves to be stated fairly. The case for letting private operators into a public service is value: that a contractor will run the thing faster, cheaper, or better than the state would manage on its own, and that the efficiency it adds is worth the margin it takes. That is the entire justification for market involvement in something like health care. If it holds, everyone gains: the public buys a better outcome than it could build for itself, and the operator earns its keep by delivering it.

The wait for Core funding remains a separate question from the administration of intake. The selection record describes service coordination responsibilities; it does not establish a contractual deadline for eliminating the funding wait.

ETWO analysis: administrative payments and access to funded care are different measures. Payments to an intake organization do not establish its profit, the effect of its work on waiting times, or the reasons for the funding queue.

Ontario selected the consortium to administer intake, coordinate access and issue funding. That establishes an administrative mandate, not evidence that families sought this governance model. Ontario’s selection record describes those responsibilities.

The available record does not quantify the arrangement’s effect on cost or wait times. Public reporting should allow families and legislators to assess its administrative performance separately from access to funded care.

The apparatus for measuring the wait is becoming more elaborate, better-funded, and more authoritative than the effort to end it. A national initiative, a community dashboard, federal strategy meetings, an AI platform, a procurement pipeline: a growing set of activities organized around a number. A diagnostic metric can improve without establishing that more children receive funded therapy.

The published metric focuses on the diagnostic queue. A complete public account would report both time to diagnosis and time to first funded service.

The fix is one sentence long. Measure time to funded therapy (referral to the first dollar of service a child actually receives) instead of time to diagnosis. Publish that number, province by province, on the same dashboard. Until the metric counts the years a diagnosed child waits with nothing, the dashboard measures only part of the crisis.

Step back far enough and the autism file starts to look like a test case for something much larger. Brown University researchers identified 574 autism therapy centers under private-equity ownership across 42 states, with nearly 80% of those acquisitions concentrated between 2018 and 2022 (Arnold et al., JAMA Pediatrics 2026, doi:10.1001/jamapediatrics.2025.5443), and a separate economic-research group found private equity firms completed the large majority of mergers and acquisitions in the sector over the same stretch (Batt, Appelbaum & Nguyen, CEPR 2023).

That parallel has limits. A dedicated search of Accerta’s corporate filings, its consortium partners, and available commercial-database records found no evidence of US private-equity ownership, investment, or acquisition in Accerta’s corporate history; it publicly holds B Corp certification and states it reinvests earnings domestically. What the pattern above documents is structural: a broader shift, elsewhere, toward intermediary-heavy administration in autism services. It is not an ownership claim about Accerta specifically.

The structural shift is still the relevant one. A layer of administrators and “navigation” services sitting between the dollar meant to buy treatment and the treatment itself, with distinct administrative and service roles: that intermediary layer is the defining feature of the system Canadians have spent generations saying they do not want. On the autism file it has arrived without anyone voting for it: a private contractor at the gate, a national initiative defining the metric, a leadership summit headlined by technology platforms, and a lobbying campaign for the contracts to run all of it.

The administrators and intermediaries, not the clinicians and therapists who do the actual work, have become the loudest, best-funded voice in the room. At the Château Laurier, the summit’s top sponsorship tier ($25,000) buys whoever holds it the lead supporter’s standing and the chance to deliver the welcoming or closing remarks.⁸ It files the federal lobbying registrations and takes the meetings at Finance Canada. And whatever its particular wording, the ask that reaches government points the same way: more administration, more data infrastructure, more platforms, more experts to manage the management. Every one of those asks routes money into the middle of the system rather than out the far end of it, where the child is.

Much of the need it claims to be meeting is need the structure itself creates. Strip the apparatus away and the underlying ask is straightforward: timely funding for the individualized supports a child needs. For some children that includes professional therapy; no single therapy or intensity fits every autistic child. Portals, navigation tools, dashboards, and summits cannot substitute for the funded service a family has been assessed to use.

Instead, less than half of estimated program spending was recorded under the core clinical services that hour belongs to.⁹ The rest is spread across other categories, which include intake and administration (the AccessOAP line, the third-largest category outside core clinical services, behind legacy programs and Urgent Response).⁹ The cited record does not establish how these spending categories affect the funding queue.

ETWO analysis: public reporting should distinguish administrative performance from access to funded services. Neither lobbying registrations nor payments alone establish that an intermediary benefits from longer waits.

Families need the system to fund appropriate support in time.